Supplementary Methods, Figures 1 - 7 from HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab

Autor: Max S. Wicha, Hasan Korkaya, Daniel F. Hayes, Dafydd G. Thomas, Celina G. Kleer, Mark L. Day, Whitney A. Chadwick, Shawn G. Clouthier, Tahra K. Luther, Nader Tawakkol, Amber N. Heath, Nallasivam Palanisamy, Christopher L. Hall, April Davis, Stephanie Daignault, Kathleen Woods Ignatoski, Ahmed A. Quraishi, Tom F. Bersano-Begey, Scott J. Dawsey, Qin Zen, Fayaz Malik, Kathleen C. Day, Suthinee Ithimakin
Rok vydání: 2023
Popis: PDF file - 491K, Supplementary Figure 3. Effect of trastazumab on stem cell marker expression. Supplementary Figure 2. Trastuzumab inhibits tertiary tumorsphere formation in luminal cell lines. Supplementary Figure 1. Representative FACS analysis demonstrating an overlap between HER2 expression and ALDH activity. Supplementary Figure 4. Trastuzumab treatment or HER2 gene knockdown reduces tumorsphere formation of MCF7 cells. Supplementary Figure 5. Rank mediated upreglation of HER2 expression in MCF7 cells. Supplementary Figure 6. Elevated HER2 expression in bone metastasis compared to matched primary luminal tumors is not due to HER2 gene amplification. Supplemental Figure 7. No significant differences in HER2 protein expression were found in matched primary tumors and bone metastasis in women with HER-positive breast cancer.
Databáze: OpenAIRE